Articles By Cyndi Root

  1. FDA Reviews Apotex's Biosimilar To Amgen's Neulasta 12/22/2014

    Apotex, a large Canadian pharmaceutical company, announced in a press release that the Food and Drug Administration (FDA) is reviewing its biosimilar in comparison to Amgen’s Neulasta.

  2. Biothera Joins Cancer Research UK Combinations Alliance 12/22/2014

    Biothera, a U.S. company focused on cancer therapies, has joined the Combinations Alliance, a joint effort between the Cancer Research UK's Centre for Drug Development and the Experimental Cancer Medicine Centre (ECMC) Network.

  3. Zafgen Starts Phase 2 Trial Of Beloranib In Severe Obesity 12/18/2014

    Zafgen, a company focusing on obesity and complex metabolic disorders, has begun a Phase 2 trial of beloranib.

  4. Carlina, Atlangram Partner On Osteoarticular Infectious Diseases Antibiotics 12/17/2014

    Carlina Technologies has partnered with Atlangram to develop innovative antibiotics for osteoarticular infectious diseases.

  5. Peregrine Reports Bavituximab Preclinical Results, Manufacturing In-House 12/17/2014

    Peregrine Pharmaceuticals announced in a press release that its bavituximab antibody treatment met with success in preclinical trials. The company also announced in a conference call that it seeks to expand in-house manufacturing of the agent, rather than outsource it to a contract and development manufacturing organization (CDMO).

  6. Oncothyreon, Array BioPharma Restructure Agreement For ONT-380 12/17/2014

    Oncothyreon and Array BioPharma have restructured their development agreement for ONT-380 (ARRY-380), an oral agent to treat metastatic breast cancer. The companies announced the deal in a press release,

  7. German Breast Group Shows Superior Activity Of Abraxane In Breast Cancer 12/16/2014

    Germany with support from industry partners Roche and Celgene, has announced that Abraxane (nab-paclitaxel) showed a clinical benefit in breast cancer patients.

  8. Cystic Fibrosis Foundation, Shire Partner On Cystic Fibrosis Treatments 12/15/2014

    The Cystic Fibrosis Foundation has partnered with Shire on new treatments for cystic fibrosis (CF).

  9. Amgen Begins Melanoma Trial Of Talimogene Laherparepvec +Merck's Keytruda 12/15/2014

    Amgen and Merck have begun a trial of Amgen’s talimogene laherparepvec in combination with Merck’s Keytruda (pembrolizumab).

  10. Takeda, Monash Partner To Develop Gastrointestinal Treatments 12/12/2014

    Monash University, Australia's largest university, has entered into a partnership with Takeda to develop treatments for gastroenterology diseases and conditions.